IGM Biosciences, Inc.
Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function

Abstract:

The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the C.mu.3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.